Regeneron, Sanofi Drop After-Hours as Covid-19 Vaccine Trial Halted

© -

By Christiana Sciaudone -- Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)fell 2.6% and Sanofi (PA:SASY)fell 1.7% in after-hours trading Thursday after the companies said phase 3 of their Covid-19 vaccine trial did not meet endpoints and they would halt the U.S. trial.

Kevzara (sarilumab) 400 mg did not meet primary and key secondary endpoints compared to a placebo. Minor positive trends were seen but were not statistically significant, and countered by negative trends in a subgroup of critical patients.

A trial of patients who received a dose of 800 mg of Kevzara was also halted.

A separate Sanofi-led trial outside the U.S. in hospitalized patients with severe and critical Covid-19 using a different dosing regimen is ongoing. offers an extensive set of professional tools for the financial markets.
Read more News on and download the new apps for Android and iOS!Copyright 2020 Fusion Media Limited. All Rights Reserved.Provided by SyndiGate Media Inc.